Von willebrand factor (recombinant) - Biologic Drug Details

Summary for von willebrand factor (recombinant)

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for von willebrand factor (recombinant)

Recent Clinical Trials for von willebrand factor (recombinant)

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Vega Therapeutics, Inc	PHASE3
Medical University of Vienna	PHASE2
Imam Abdulrahman Bin Faisal University	PHASE3

See all von willebrand factor (recombinant) clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for von willebrand factor (recombinant) Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for von willebrand factor (recombinant) Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Takeda Pharmaceuticals U.s.a., Inc.	VONVENDI	von willebrand factor (recombinant)	For Injection	125577	10,066,020	2037-07-28	DrugPatentWatch analysis and company disclosures
Takeda Pharmaceuticals U.s.a., Inc.	VONVENDI	von willebrand factor (recombinant)	For Injection	125577	10,519,208	2039-02-28	DrugPatentWatch analysis and company disclosures
Takeda Pharmaceuticals U.s.a., Inc.	VONVENDI	von willebrand factor (recombinant)	For Injection	125577	11,124,578	2039-04-30	DrugPatentWatch analysis and company disclosures
Takeda Pharmaceuticals U.s.a., Inc.	VONVENDI	von willebrand factor (recombinant)	For Injection	125577	11,492,376	2040-12-22	DrugPatentWatch analysis and company disclosures
Takeda Pharmaceuticals U.s.a., Inc.	VONVENDI	von willebrand factor (recombinant)	For Injection	125577	11,773,177	2041-08-23	DrugPatentWatch analysis and company disclosures
Takeda Pharmaceuticals U.s.a., Inc.	VONVENDI	von willebrand factor (recombinant)	For Injection	125577	9,074,003	2034-01-10	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for von willebrand factor (recombinant) Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Takeda Pharmaceuticals U.s.a., Inc.	VONVENDI	von willebrand factor (recombinant)	For Injection	125577	10,232,015	2037-06-14	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	VONVENDI	von willebrand factor (recombinant)	For Injection	125577	6,100,061	2018-06-19	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	VONVENDI	von willebrand factor (recombinant)	For Injection	125577	6,114,146	2015-11-14	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	VONVENDI	von willebrand factor (recombinant)	For Injection	125577	6,960,352	2022-09-12	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	VONVENDI	von willebrand factor (recombinant)	For Injection	125577	9,120,873	2029-08-21	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	VONVENDI	von willebrand factor (recombinant)	For Injection	125577	9,707,269	2033-03-15	Patent claims search

International Patents for von willebrand factor (recombinant)

Country	Patent Number	Estimated Expiration
Japan	6694409
European Patent Office	2640749
Taiwan	201623335
Poland	2604693
World Intellectual Property Organization (WIPO)	2013001517
Lithuania	2914291

Supplementary Protection Certificates for von willebrand factor (recombinant)

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2023C/518	Belgium		PRODUCT NAME: SUTIMLIMAB; AUTHORISATION NUMBER AND DATE: EU/1/22/1687 20221123
PA2023510,C2914291	Lithuania		PRODUCT NAME: SUTIMLIMABAS; REGISTRATION NO/DATE: EU/1/22/1687 20221115
LUC00303	Luxembourg		PRODUCT NAME: SUTIMLIMAB; AUTHORISATION NUMBER AND DATE: EU/1/22/1687 20221123
23C1019	France		PRODUCT NAME: SUTIMLIMAB; REGISTRATION NO/DATE: EU/1/22/1687 20221123
122023000018	Germany		PRODUCT NAME: SUTIMLIMAB; REGISTRATION NO/DATE: EU/1/22/1687 20221115
301232	Netherlands		DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT

Von willebrand factor (recombinant) Market Analysis and Financial Projection

Last updated: February 13, 2026

What Are the Current Market Dynamics for Recombinant Von Willebrand Factor (vWF)?

The recombinant form of von Willebrand factor (vWF) addresses a high unmet medical need for patients with von Willebrand disease (vWD), a hereditary bleeding disorder affecting approximately 1 in 100,000 individuals globally. The biologic is positioned within a niche market characterized by increasing adoption driven by advances in manufacturing and a shift toward recombinant products to reduce pathogen transmission risks associated with plasma-derived therapies.

Key Drivers

• Growing Patient Base: The global prevalence of vWD remains stable, but increased awareness and improved diagnostic techniques have expanded diagnosed cases. Estimated at about 20,000 to 30,000 patients in the U.S. alone,[1] growth in diagnosis contributes to demand.

• Shift Toward Recombinant Product Usage: Recombinant vWF offers higher purity, consistent supply, and lower infection risk compared to plasma-derived options. Regulators, including the FDA and EMA, favor recombinant biologics, facilitating market approval and adoption.

• Clinical Efficacy and Safety Profile: Clinical trials demonstrate recombinant vWF effectively manages bleeding episodes with favorable safety, boosting clinician confidence. The U.S. approval of brands like Takeda's Vonvendi (desmopressin) and SHP635 (recombinant vWF) signifies regulatory endorsement.

• Competitive Landscape: Currently, there are limited FDA-approved recombinant vWF products. The market features plasma-derived options and emerging recombinant formulations. Entry is possible for new entrants with differentiated products.

• Pricing and Reimbursement: Premium pricing for recombinant vWF, driven by manufacturing costs and safety benefits, influences market dynamics. Reimbursement policies vary across regions, impacting uptake.

Market Challenges

• Manufacturing Complexities: Recombinant vWF production involves sophisticated cell line engineering, large-scale purification, and stability management, elevating costs and limiting availability.

• Cost-Effectiveness Considerations: Payors scrutinize premium prices relative to plasma-derived alternatives, influencing formulary inclusion.

• Limited Awareness and Diagnoses: Despite improved diagnostics, target patient identification remains incomplete, constraining demand.

• Regulatory and Patent Barriers: Navigating regulatory pathways and patent landscapes poses barriers to new competitors.

Market Size and Forecast

• The global vWF market, projected at USD 600 million in 2022, is expected to grow at a compound annual growth rate (CAGR) of 6-8% through 2030, driven by rising diagnosis rates and recombinant product adoption.[2]

Year	Market Size (USD Million)	CAGR	Notes
2022	600	—	Base year
2025	750 - 810	6-8%	Estimated with increasing recombinant adoption
2030	950 - 1,050	6-8%	Market expansion driven by new product launches

How Is the Financial Trajectory Evolving for Recombinant vWF?

Revenue Trends

• Companies developing recombinant vWF expect initial revenues to be modest, reflecting limited market penetration in early commercialization phases. Rapid growth is anticipated as approvals expand, especially in regions with advanced healthcare infrastructure.

• Takeda's Vonvendi represented the first recombinant vWF approval (EMA, 2016; FDA, 2019), with revenue contributions primarily from the U.S. and Europe.

Investment and R&D Expenditure

• R&D costs for recombinant vWF do not solely include clinical development but also include process development, scale-up, and biosimilar formulation optimization.

• Leading firms report R&D budgets in the range of USD 50 million to USD 200 million for biologics, with recombinant vWF-specific R&D representing a smaller fraction due to existing platform technologies.

Profitability Outlook

• Profit margins are constrained during initial launch phases due to high manufacturing costs and market penetration challenges.

• Margins are expected to improve with increased process efficiencies, larger market share, and broader reimbursement coverage.

Pricing Strategies

• Premium pricing strategies are common, with prices often exceeding USD 150,000 annually per patient. This pays for complex manufacturing and safety assurances.

• Payer negotiations hinge on demonstrating cost savings from reduced adverse events and safety improvements versus plasma-derived therapies.

Investment Risks

• Technology risks related to manufacturing scale-up.

• Regulatory risks if safety or efficacy profiles differ from plasma-derived products.

• Market acceptance risk, especially if clinicians prefer established plasma-based options or if biosimilar recombinant vWF products emerge.

What Are the Key Forecasting Parameters to Consider?

Parameter	Impact	Data Point
Market penetration rate	Drives revenue growth	Expected at 10-30% in initial years based on approval and adoption rates
Price per unit	Significantly impacts revenue and profitability	USD 150,000+ per patient annually
R&D investment	Affects long-term innovation and product pipeline	USD 50-200 million for biologics development
Regulatory environment	Influences approval timelines and market access	Stringent in developed markets, variable globally
Reimbursement policies	Affect product uptake and revenue	Favorable in the U.S. and Europe; variable elsewhere

Summary: Opportunities and Risks

Opportunities

• Expansion into emerging markets with increasing diagnostic rates.

• Development of next-generation recombinant vWF with improved pharmacokinetics.

• Strategic partnerships to scale manufacturing and reduce costs.

Risks

• Entry of biosimilar competitors could reduce market prices.

• Manufacturing complexities limit availability and scalability.

• Variability in clinician preference for plasma vs. recombinant products.

---

Key Takeaways

• Recombinant vWF has a limited but growing market share driven by safety concerns and manufacturing advantages.

• The global market is forecast to grow at a CAGR of approximately 6-8% through 2030, reaching USD 950 million to USD 1 billion.

• Revenue growth hinges on regulatory approvals, pricing strategies, and reimbursement coverage.

• High manufacturing costs and market acceptance pose barriers to rapid growth.

• Strategic investments in innovative formulations and emerging markets can expand revenue opportunities.

FAQs

Q1: How does recombinant vWF compare to plasma-derived options in safety?
A: Recombinant vWF eliminates risks of pathogen transmission linked to plasma-derived products, offering a safer option for patients.

Q2: What are the main barriers to market expansion?
A: Manufacturing complexity, high costs, limited clinician awareness, and reimbursement challenges hinder rapid adoption.

Q3: Which regions are the primary growth drivers?
A: North America and Europe drive initial growth due to advanced healthcare infrastructure; Asia-Pacific presents emerging opportunities.

Q4: Are biosimilars a threat?
A: Yes, biosimilar recombinant vWF products could drive prices down and impact margins once approved.

Q5: What is the timeline for new product approvals?
A: Regulatory approval timelines range from 1 to 3 years post-clinical trial completion, depending on jurisdiction.

---

References

[1] calculation based on prevalence data and diagnosed patient estimates.
[2] Market research reports from GlobalData, EvaluatePharma, and industry analyses (2022).